EGEwa Głąb-Jabłońska

Ewa Głąb-Jabłońska

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ewa Głąb-Jabłońska has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Dried Blood Spot-Based Monitoring of Dietary Treatment in Children, Adolescents, and Young Adults with Inherited Disorders of Amino Acid Metabolism: A Four-Year Pilot Study

    by Agnieszka Kowalik, Ewa Głąb-Jabłońska, Joanna Taybert, Marta Nogalska, Mariola Sasin-Rokita, Magdalena Chełchowska, Joanna Myszkowska-Ryciak, Jolanta Sykut-Cegielska

    Background: Regular biochemical monitoring is essential for the safe and effective dietary treatment of inherited disorders of amino acid metabolism. However, conventional venous blood sampling may limit monitoring frequency and increase the burden on families. This study evaluated the feasibility and clinical usefulness of home-collected dried blood spot (DBS) samples analyzed using tandem mass spectrometry and additional chromatographic methods for dietary monitoring in inherited disorders of amino acid metabolism other than phenylketonuria. Methods: Between 2022 and 2025, children, adolescents, and young adults aged between 4 months and 20.5 years who were followed at a national metabolic center were monitored using DBS samples. The initial cohort included patients with maple syrup urine disease, tyrosinemia type III, homocystinuria, glutaric aciduria type 1, methylmalonic aciduria, isovaleric aciduria, argininosuccinic aciduria, methionine adenosyltransferase I/III deficiency, beta-ketothiolase deficiency, propionic aciduria, gyrate atrophy, and citrullinemia type 1. Disease-specific amino acids and metabolites were assessed to guide individualized dietary recommendations. Results: The number of monitored patients ranged from 24 to 40 per year. Overall annual completion rates of planned DBS measurements ranged from 56.7% to 73.0%, with additional clinically indicated samples collected in selected patients. DBS monitoring detected abnormal metabolite concentrations and supported dietary interventions, particularly in maple syrup urine disease, glutaric aciduria type 1, homocystinuria, tyrosinemia type III, and MAT I/III deficiency. In several other disorders, routine monthly DBS monitoring showed limited additional clinical value. Conclusions: DBS-based monitoring is a feasible approach that may support individualized dietary management in selected inherited disorders of amino acid metabolism, especially in early childhood and during periods of increased metabolic risk.

    • 4 December 2025
      • Vol. 29  (1) , 227-233
    Open Access

    Medium-chain Acyl-CoA Dehydrogenase Deficiency Identified by MS/MS Newborn Screening Challenges.

    by Ewa Głąb-Jabłońska, Joanna Taybert, Anna Wiśniewska, Mariola Sasin-Rokita, Mariusz Ołtarzewski, Magdalena Chełchowska

    Medium-chain acyl-CoA dehydrogenase (MCAD) deficiency is an inborn error of metabolism resulting in the absence or reduced activity of the enzyme responsible for the β-oxidation of medium-chain fatty acids. MCAD deficiency can lead to metabolic decompensation, presenting as hypoketotic hypoglycaemia, hepatic encephalopathy (Reye-like syndrome), or death regardless of the patient's age. Blood samples in the national newborn screening programme were collected using 903 filter paper (dry blood spot - DBS). Routine dried blood spots from newborn screening (NBS) were analysed by flow injection and derivatised tandem mass spectrometry method (MS/MS). Positive screening cases in the MCAD deficiency profile were verified through GC/MS urine organic acid profiling and enzymatic and/or molecular testing. A total of 3,806,166 newborns were screened between 2014-2024, resulting in the identification of 94 cases of MCAD deficiency. Analysis of the obtained results revealed a consistent pattern in the levels of octanoylcarnitine (C8), hexanoylcarnitine (C6), and decanoylcarnitine (C10) acylcarnitines, as well as the C8/C10 ratio across these cases. Only one case of confirmed MCAD deficiency with an atypical acylcarnitine profile was found. The use of tandem mass spectrometry has enabled the inclusion of MCAD deficiency in newborn screening programmes. This has facilitated early detection, diagnosis, and initiation of therapeutic interventions to prevent metabolic decompensation. We emphasize the need for repeated sampling and further testing if C8 is even slightly elevated.

    • 28 March 2025
      • Vol. 29  (1) , 1-9
    Open Access

    Leptin, Leptin Receptor Concentrations and Free Leptin Index (FLI) in Polish Healthy Children and Adolescents.

    by Joanna Gajewska, Grażyna Rowicka, Witold Klemarczyk, Ewa Głąb-Jabłońska, Jadwiga Ambroszkiewicz

    Leptin physiology in children is crucial for diagnosing and managing pediatric endocrine and metabolic disorders. The aim of this study was to assess the values of leptin, leptin receptor (sOB-R), and free leptin index (FLI) depending on age and sex in healthy Polish children and adolescents. A total of 236 children and adolescents aged 1-18 years were recruited. Leptin and leptin receptor concentrations were determined by immunoenzymatic methods. FLI values were calculated as leptin divided by sOB-R concentrations. In 114 children between the ages of 5 and 10 years, a measurement of fat mass was assessed by dual-energy X-ray absorptiometry. The studied groups of girls and boys were of similar age and did not differ in terms of weight, height, body mass index (BMI), BMI Z-score values, or leptin receptor concentrations. Leptin concentrations and FLI were higher by about 50% (p=0.006; p=0.051, respectively) in girls than boys. Positive correlations were found between leptin and age, BMI, and BMI Z-score values (r=0.562, r=0.563, p=0.397; p<0.001, respectively), and even stronger between FLI and age, BMI, and BMI Z-score values (r=0.670, r=0.632, p=0.409; p<0.001, respectively). The results concerning leptin and leptin receptor concentrations and FLI values in healthy individuals may be useful in clinical practice in early identification of children and adolescents with an unfavorable adipokine profile resulting in a predisposition to the development of obesity and obesity-related complications. These markers may also be helpful in monitoring therapy effectiveness in patients with obesity, diabetes, and metabolic syndrome.


    • 19 April 2024
      • Vol. 28  (1) , 14-22
    Open Access

    Assessment of Biochemical Bone Turnover Markers in Polish Healthy Children and Adolescents

    by Joanna Gajewska, Magdalena Chełchowska, Grażyna Rowicka, Witold Klemarczyk, Ewa Głąb-Jabłońska, Jadwiga Ambroszkiewicz

    Assessing bone turnover in paediatric populations is crucial for understanding the physiological changes occurring during skeletal development and identifying potential abnormalities. The objective of this study was to assess osteocalcin (OC), bone alkaline phosphatase (BALP), and C-terminal telopeptide of type I collagen (CTX-I) levels reflecting bone formation and resorption for age and sex in Polish healthy children and adolescents. A total of 355 healthy normal-weight children and adolescents (46.5% girls) aged 1–18 years old were recruited. Total body less head (TBLH) and spine L1-L4 were used in children to assess bone mineral density (BMD) by dual-energy X-ray absorptiometry (DXA). Bone marker concentrations were determined by immunoenzymatic methods. Bone marker levels in girls and boys started with higher values in the first year of life and subsequently decreased until reaching a nadir during the prepubertal period. The pubertal peak values of bone markers were reached at 11–13 years old in boys and at 9–11 years old in girls. After puberty, the adolescents showed a gradual decline in bone marker concentrations to the values observed in adults. We found positive correlations between OC level and TBLH-BMD (r = 0.329, p = 0.002), TBLH-BMD Z-score (r = 0.245, p = 0.023), and L1-L4 BMD (r = 0.280, p = 0.009) in the prepubertal group. We showed serum levels of bone turnover markers—BALP, OC, and CTX-I—in relation to age and sex in healthy Polish children and adolescents. The age intervals of these markers for girls and boys aged 1–18 years old may be clinically useful in the assessment of bone metabolism in individuals with skeletal disorders.